Broadwood Partners, L.P. Purchases 3,620 Shares of STAAR Surgical (NASDAQ:STAA) Stock

STAAR Surgical (NASDAQ:STAA) major shareholder Broadwood Partners, L.P. bought 3,620 shares of the business’s stock in a transaction on Thursday, March 27th. The stock was bought at an average cost of $17.48 per share, with a total value of $63,277.60. Following the completion of the purchase, the insider now directly owns 12,424,944 shares in the company, valued at approximately $217,188,021.12. The trade was a 0.03 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Large shareholders that own 10% or more of a company’s stock are required to disclose their sales and purchases with the SEC.

Broadwood Partners, L.P. also recently made the following trade(s):

• On Tuesday, March 25th, Broadwood Partners, L.P. acquired 34,296 shares of STAAR Surgical stock. The stock was purchased at an average cost of $17.44 per share, with a total value of $598,122.24.
• On Thursday, March 20th, Broadwood Partners, L.P. bought 108,720 shares of STAAR Surgical stock. The shares were purchased at an average cost of $17.96 per share, for a total transaction of $1,952,611.20.
• On Tuesday, March 18th, Broadwood Partners, L.P. purchased 93,124 shares of STAAR Surgical stock. The shares were purchased at an average price of $17.54 per share, with a total value of $1,633,394.96.
• On Monday, March 3rd, Broadwood Partners, L.P. acquired 249,503 shares of STAAR Surgical stock. The stock was acquired at an average price of $16.64 per share, with a total value of $4,151,729.92.
• On Thursday, February 27th, Broadwood Partners, L.P. bought 259,316 shares of STAAR Surgical stock. The stock was acquired at an average price of $17.05 per share, for a total transaction of $4,421,337.80.
• On Friday, February 14th, Broadwood Partners, L.P. acquired 36,532 shares of STAAR Surgical stock. The shares were acquired at an average cost of $15.49 per share, with a total value of $565,880.68.
• On Wednesday, February 12th, Broadwood Partners, L.P. bought 259,616 shares of STAAR Surgical stock. The stock was bought at an average cost of $14.96 per share, for a total transaction of $3,883,855.36.
• On Thursday, January 16th, Broadwood Partners, L.P. purchased 8,221 shares of STAAR Surgical stock. The shares were bought at an average price of $21.50 per share, with a total value of $176,751.50.
• On Tuesday, January 14th, Broadwood Partners, L.P. acquired 21,155 shares of STAAR Surgical stock. The stock was bought at an average price of $21.46 per share, for a total transaction of $453,986.30.

STAAR Surgical Stock Performance

Shares of STAA opened at $17.79 on Friday. STAAR Surgical has a 1 year low of $13.50 and a 1 year high of $52.68. The stock has a market capitalization of $877.49 million, a PE ratio of -43.39 and a beta of 0.66. The stock has a 50-day simple moving average of $19.43 and a 200-day simple moving average of $25.20.

Analysts Set New Price Targets

A number of analysts have issued reports on the company. Piper Sandler cut their target price on STAAR Surgical from $40.00 to $16.00 and set a “neutral” rating on the stock in a research report on Wednesday, February 12th. Needham & Company LLC reiterated a “hold” rating on shares of STAAR Surgical in a report on Thursday, February 27th. William Blair cut STAAR Surgical from an “outperform” rating to a “market perform” rating in a report on Wednesday, February 12th. Stifel Nicolaus dropped their target price on STAAR Surgical from $38.00 to $20.00 and set a “buy” rating for the company in a research report on Wednesday, February 12th. Finally, Stephens reissued an “equal weight” rating and set a $17.00 price target on shares of STAAR Surgical in a research report on Tuesday, March 18th. Two research analysts have rated the stock with a sell rating, eight have issued a hold rating and one has issued a buy rating to the company’s stock. Based on data from MarketBeat.com, STAAR Surgical presently has a consensus rating of “Hold” and an average target price of $25.29.

Institutional Trading of STAAR Surgical

Several hedge funds have recently added to or reduced their stakes in STAA. Geode Capital Management LLC increased its position in shares of STAAR Surgical by 2.7% in the 3rd quarter. Geode Capital Management LLC now owns 1,174,499 shares of the medical instruments supplier’s stock valued at $43,641,000 after purchasing an additional 31,212 shares during the last quarter. HighTower Advisors LLC purchased a new position in STAAR Surgical in the third quarter valued at $336,000. Polar Asset Management Partners Inc. raised its stake in STAAR Surgical by 44.3% in the third quarter. Polar Asset Management Partners Inc. now owns 168,800 shares of the medical instruments supplier’s stock valued at $6,271,000 after buying an additional 51,800 shares in the last quarter. JPMorgan Chase & Co. raised its stake in STAAR Surgical by 411.7% in the third quarter. JPMorgan Chase & Co. now owns 214,750 shares of the medical instruments supplier’s stock valued at $7,978,000 after buying an additional 172,779 shares in the last quarter. Finally, Defender Capital LLC. lifted its holdings in STAAR Surgical by 3.5% during the 4th quarter. Defender Capital LLC. now owns 701,567 shares of the medical instruments supplier’s stock worth $17,041,000 after buying an additional 23,950 shares during the last quarter. Institutional investors and hedge funds own 96.70% of the company’s stock.

STAAR Surgical Company Profile

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia.